Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycophenolate mofetil in primary glomerulopathies.

V Sepe1, C Libetta, M G Giuliano

  • 1Unit of Nephrology, Dialysis and Transplantation, Fondazione I.R.C.C.S. Policlinico San Matteo and Chair of Nephrology, University of Pavia, Pavia, Italy. vsepe@libero.it

Kidney International
|November 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topological insulator metamaterial with giant circular photogalvanic effect.

Science advances·2021
Same author

Gender differences and occupational factors for the risk of obesity in the Italian working population.

BMC public health·2020
Same author

Infrared dielectric metamaterials from high refractive index chalcogenides.

Nature communications·2020
Same author

The end of measles and congenital rubella: an achievable dream?

Annali di igiene : medicina preventiva e di comunita·2017
Same author

Cost-effectiveness of kidney transplantation from DCD in Italy.

Transplantation proceedings·2014
Same author

Theonellasterone, a steroidal metabolite isolated from a Theonella sponge, protects peroxiredoxin-1 from oxidative stress reactions.

Chemical communications (Cambridge, England)·2014

Mycophenolate mofetil shows promise for minimal change nephropathy, potentially reducing steroid use. However, its effectiveness in other primary glomerulopathies like focal segmental glomerulosclerosis and IgA nephropathy requires further investigation through robust clinical trials.

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Mycophenolate mofetil is an immunosuppressant that inhibits purine biosynthesis and lymphocyte proliferation.
  • Unlike calcineurin inhibitors, it is not nephrotoxic and is established in solid-organ transplantation.
  • It is increasingly used for autoimmune diseases and primary glomerulopathies.

Purpose of the Study:

  • To review the current literature on mycophenolate mofetil for treating primary glomerulopathies.
  • To assess its efficacy and safety in various glomerular diseases.
  • To identify gaps in evidence and guide future research.

Main Methods:

  • Literature review of studies on mycophenolate mofetil in primary glomerulopathies.
  • Analysis of treatment outcomes in minimal change nephropathy, focal segmental glomerulonephritis, idiopathic membranous nephropathy, and IgA nephropathy.

Related Experiment Videos

  • Evaluation of evidence quality and statistical significance.

    • Main Results:

    • Encouraging results in minimal change nephropathy, suggesting potential steroid-sparing effects, especially in young patients.
    • Less encouraging outcomes in medium-to-high risk focal segmental glomerulonephritis and idiopathic membranous nephropathy.
    • Conflicting results reported for IgA nephropathy in controlled trials.

    Conclusions:

    • Mycophenolate mofetil demonstrates potential benefits in specific primary glomerulopathies like minimal change nephropathy.
    • Evidence for its efficacy in other conditions such as FSGS, iMN, and IgA nephropathy is limited or conflicting.
    • High-quality randomized controlled trials are essential to establish the definitive effectiveness of mycophenolate mofetil in primary glomerulopathies.